NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEVELOPMENTAL DISEASES, NERVE DEMYELINATION DISEASES AND NEURODEGENERATIVE DISEASES BY LOCAL AND OR SYSTEMIC INJECTIONS OF A MIXTURE OF TRANSGENIC MESENCHYMAL STEM CELLS OR OTHER SOMATIC CELLS EXPRESSING NEUROREGENERATIVE AND NEUROPROTECTIVE FACTORS ALONE OR IN COMBINATIONS OF TWO OR MORE THERAPEUTIC PROTEINS.
The immune dysfunction and autoimmune phenomena including dysfunction of Natural Killer (NK) cells play an important role in the neurodevelopmental disorders. Inflammatory Demyelinating Polyneuropathy (IDP) can be acute (AIDP- Acute Inflammatory Demyelinating Polyneuropathy) or chronic (CIDP- Chronic Inflammatory Demyelinating Polyneuropathy) and can manifest into sudden or chronic demyelination of nerves leading to motor manifestations. Guillain-Barr syndrome (GBS) is characterized by acute areflexic paralysis and is the most frequent cause of acute flaccid paralysis worldwide. Up to 20% of the patients of GBS remain severely disabled and approximately 5 % die, despite immunotherapy. Autistic spectrum disorder patients are known to be afflicted also with gastrointestinal immune related pathology characterized by lymphoid nodular hyperplasia and enterocolitis. Our invention of using the transgenic mesenchymal stem cells with expression of human ciliary neurotrophic factor (CNTF), Brain Derived Neurotrophic Factor (BDNF), Glial cell derived neurotrophic factor (GDNF), nerve growth factor (NGF), neurotrophin 3 (NTF-3), neurotrophin 4 (NTF-4), hepatocyte growth factor (HGF) provides excellent novel therapy for the neurodegenerative and neuro- inflammatory conditions. At the same time, expression anti-inflammatory interleukin 10 (IL-10) and interleukin 4 (IL-4) in the background of these proteins helps in minimizing the ongoing neurodegeneration. The invention is neuro-regenerative and neuro- protective and will improve the quality of life for millions of patients.
